GlassScriptPhysician profile
Kendrick Knoll Henderson
NPI 1760452577
$28,396.60
in general payments reported to CMS, 2019-2025
76 companies · $4,422 in 2025
The $4,422 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,867 · 2020: $2,610 · 2021: $3,402 · 2022: $4,347 · 2023: $4,267 · 2024: $5,482 · 2025: $4,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Travel and Lodging: $962 · Education: $88.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,119.73 |
| Travel and Lodging | $962.40 |
| Education | $88.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,703.83 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,026.22 | 2019-2025 | |
| Ucb, INC. | $1,351.59 | 2019-2025 | Nayzilam, Rystiggo, Briviact |
| E.R. Squibb & Sons, L.L.C. | $1,325.63 | 2020-2024 | |
| Teva Pharmaceuticals USA, INC. | $1,156.62 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Emd Serono, INC. | $1,101.24 | 2019-2025 | Mavenclad, Mavenclad |
| Pfizer INC. | $1,100.04 | 2019-2025 | |
| Biogen, INC. | $1,039.05 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Amgen INC. | $901.64 | 2019-2025 | Uplizna, Aimovig |
| Genentech USA, INC. | $896.44 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Alexion Pharmaceuticals, INC. | $857.50 | 2019-2024 | Ultomiris, Soliris |
| Lilly USA, LLC | $745.22 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Sk Life Science, INC. | $674.25 | 2020-2025 | Xcopri |
| Celgene Corporation | $655.40 | 2021-2025 | Zeposia |
| Lundbeck LLC | $640.58 | 2019-2025 | Vyepti, Rexulti |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendrick Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.